AbbVie Inc ABBV

What the company does

AbbVie Inc is a mega-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $504.8B, based in the USA.

It employs about 57,000 people and has been listed since Jan 02, 2013.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.

Cheap or expensive? relatively expensive

Its price-to-earnings (P/E) is 80.7 versus 41.9 for 4 direct peers — relatively expensive.

Revenue is growing 10% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 16.2 — they expect higher earnings.

The average analyst price target is 284.79, 0% below the current price (their view, not ours).

The stock sits at 94% of its one-year range (0% = the low, 100% = the high).

The risks

• • Quarterly report in 5 days (2026-10-30) — a day the stock can move a lot.

Strengths

• ✅ Profitable — 21 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Most analysts rate it buy (24 vs 1).
• ✅ Pays a dividend (2.4% a year).

What changed this week

Over the past week the stock rose 0.1% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

This week's news

• AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases finance.yahoo.com · 2026-10-24
  What the article says

  AbbVie's analyst narrative has shifted again, with fair value in one model now set at US$284.79 compared with US$278.61 previously, and other price targets clustering in a wide US$260 to US$325 range. Recent commentary links these higher targets to confidence in AbbVie's portfolio across immunology, neuroscience and… source ↗

• U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease finance.yahoo.com · 2026-10-23
  What the article says

  Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni and endoscopic… source ↗

• BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? finance.yahoo.com · 2026-10-23
  What the article says

  Bristol Myers Squibb BMY and AbbVie ABBV are two leading pharma/biotech players with diversified portfolios and a strong global presence. BMY has built a robust portfolio comprising drugs for oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. AbbVie is a global, diversified… source ↗

• Global Dental Soft Tissue Wound Care Market Size, Share, and Forecast by Product, 2026-2032 | Plug, Tape, and Foam Demand to Drive 11.8% CAGR and a $390 Million Market finance.yahoo.com · 2026-10-23
  What the article says

  Company Logo The global dental soft tissue wound care market is projected to grow from nearly $180 million in 2025 to nearly $390 million by 2032, a new Research and Markets report finds, with ZimVie leading ahead of AbbVie and Henry Schein, though cost sensitivity and limited reimbursement persist. Dublin, Oct. 23,… source ↗

• AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release finance.yahoo.com · 2026-10-23
  What the article says

  The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock… source ↗

• Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says finance.yahoo.com · 2026-10-22
  What the article says

  Avalo Therapeutics' (AVTX) abdakibart remains promising for hidradenitis suppurativa, with phase 2 r PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in source ↗

What changed since last week

• New risk flag: earnings report coming up.